Cargando…

Neuroleptic‐induced Parkinsonism: Clinicopathological study

BACKGROUND: Drug‐induced parkinsonism is a well‐known complication of several different drugs—the most common being neuroleptic‐induced parkinsonism. However, very few autopsies have been reported in such cases. METHODS: Patients assessed at Movement Disorders Clinic Saskatchewan are offered brain a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shuaib, Umar A., Rajput, Ali H., Robinson, Christopher A., Rajput, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064745/
https://www.ncbi.nlm.nih.gov/pubmed/26660063
http://dx.doi.org/10.1002/mds.26467
_version_ 1782460221307748352
author Shuaib, Umar A.
Rajput, Ali H.
Robinson, Christopher A.
Rajput, Alex
author_facet Shuaib, Umar A.
Rajput, Ali H.
Robinson, Christopher A.
Rajput, Alex
author_sort Shuaib, Umar A.
collection PubMed
description BACKGROUND: Drug‐induced parkinsonism is a well‐known complication of several different drugs—the most common being neuroleptic‐induced parkinsonism. However, very few autopsies have been reported in such cases. METHODS: Patients assessed at Movement Disorders Clinic Saskatchewan are offered brain autopsy. Detailed clinical records are kept. RESULTS: Brains were obtained from 7 drug‐induced parkinsonism patients with parkinsonian symptom onset coinciding with use of drugs known to produce parkinsonism. Six were on antipsychotics and 1 was on metoclopramide. Three cases were treated with levodopa for parkinsonism. In two cases, parkinsonian features reversed after stopping the offending agent. Both had autopsy evidence of preclinical PD. In 4 of the remaining 5, dopamine‐blocking drugs were continued until death. In 4 of those 5, brain histology revealed no cause for the parkinsonism, but 1 had mild SN neuronal loss without Lewy bodies. CONCLUSION: This study shows that reversal of parkinsonism after discontinuing offending drugs does not indicate absence of underlying pathology. Neuroleptics can unmask preclinical PD in patients with insufficient SN damage for the disease to manifest clinically. Though the mechanism of sustained parkinsonian features after discontinuing neuroleptics remains to be established, it is unlikely that dopamine receptor block leads to retrograde SN neuronal degeneration. Furthermore, l‐dopa does not appear to be toxic to SN. © 2015 International Parkinson and Movement Disorder Society
format Online
Article
Text
id pubmed-5064745
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50647452016-10-19 Neuroleptic‐induced Parkinsonism: Clinicopathological study Shuaib, Umar A. Rajput, Ali H. Robinson, Christopher A. Rajput, Alex Mov Disord Research Articles BACKGROUND: Drug‐induced parkinsonism is a well‐known complication of several different drugs—the most common being neuroleptic‐induced parkinsonism. However, very few autopsies have been reported in such cases. METHODS: Patients assessed at Movement Disorders Clinic Saskatchewan are offered brain autopsy. Detailed clinical records are kept. RESULTS: Brains were obtained from 7 drug‐induced parkinsonism patients with parkinsonian symptom onset coinciding with use of drugs known to produce parkinsonism. Six were on antipsychotics and 1 was on metoclopramide. Three cases were treated with levodopa for parkinsonism. In two cases, parkinsonian features reversed after stopping the offending agent. Both had autopsy evidence of preclinical PD. In 4 of the remaining 5, dopamine‐blocking drugs were continued until death. In 4 of those 5, brain histology revealed no cause for the parkinsonism, but 1 had mild SN neuronal loss without Lewy bodies. CONCLUSION: This study shows that reversal of parkinsonism after discontinuing offending drugs does not indicate absence of underlying pathology. Neuroleptics can unmask preclinical PD in patients with insufficient SN damage for the disease to manifest clinically. Though the mechanism of sustained parkinsonian features after discontinuing neuroleptics remains to be established, it is unlikely that dopamine receptor block leads to retrograde SN neuronal degeneration. Furthermore, l‐dopa does not appear to be toxic to SN. © 2015 International Parkinson and Movement Disorder Society John Wiley and Sons Inc. 2015-12-11 2016-03 /pmc/articles/PMC5064745/ /pubmed/26660063 http://dx.doi.org/10.1002/mds.26467 Text en © 2015 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Shuaib, Umar A.
Rajput, Ali H.
Robinson, Christopher A.
Rajput, Alex
Neuroleptic‐induced Parkinsonism: Clinicopathological study
title Neuroleptic‐induced Parkinsonism: Clinicopathological study
title_full Neuroleptic‐induced Parkinsonism: Clinicopathological study
title_fullStr Neuroleptic‐induced Parkinsonism: Clinicopathological study
title_full_unstemmed Neuroleptic‐induced Parkinsonism: Clinicopathological study
title_short Neuroleptic‐induced Parkinsonism: Clinicopathological study
title_sort neuroleptic‐induced parkinsonism: clinicopathological study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064745/
https://www.ncbi.nlm.nih.gov/pubmed/26660063
http://dx.doi.org/10.1002/mds.26467
work_keys_str_mv AT shuaibumara neurolepticinducedparkinsonismclinicopathologicalstudy
AT rajputalih neurolepticinducedparkinsonismclinicopathologicalstudy
AT robinsonchristophera neurolepticinducedparkinsonismclinicopathologicalstudy
AT rajputalex neurolepticinducedparkinsonismclinicopathologicalstudy